Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
CFO resigned
Acq. announced
CC transcript
Director departure

AVANIR PHARMACEUTICALS, INC. (AVNR) Create: Alert

All | News | Filings
Date FiledTypeDescription
01/13/2015 8-K Quarterly results
12/02/2014 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "Agreement and Plan of Merger, by and among Otsuka Pharmaceutical Co., Ltd., Bigarade Corporation and Avanir Pharmaceuticals, Inc",
"AVANIR PHARMACEUTICALS TO BE ACQUIRED BY OTSUKA PHARMACEUTICAL FOR $3.5 BILLION"
11/26/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Avanir Pharmaceuticals Receives Complete Response Letter from FDA on AVP-825 NDA"
11/12/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/07/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Avanir Pharmaceuticals Announces Preliminary Feedback from the FDA on AVP-825 for the Acute Treatment of Migraine"
09/25/2014 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Underwriting Agreement, by and among Avanir Pharmaceuticals, Inc., J.P. Morgan Securities LLC, Deutsche Bank Securities Inc. and Merrill Lynch, Pierce, Fenner & Smith Incorporated",
"Opinion of Gibson, Dunn & Crutcher LLP"
09/15/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Avanir Pharmaceuticals Announces Positive Phase II Trial Results for AVP-923 in Treatment of Agitation in Patients with Alzheimer's Disease"
08/05/2014 8-K Quarterly results
Docs: "Avanir Pharmaceuticals Reports Fiscal 2014 Third Quarter Financial and Business Update"
05/07/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Third Amendment to Sales Agreement",
"Opinion of Gibson, Dunn & Crutcher LLP"
05/06/2014 8-K Quarterly results
Docs: "Avanir Pharmaceuticals Reports Fiscal 2014 Second Quarter Financial and Business Results"
05/05/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Avanir Pharmaceuticals Prevails in NUEDEXTA Patent Trial Resulting in Exclusivity Through 2026"
03/19/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/19/2014 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "Certificate of Amendment to the Certificate of Incorporation of Avanir Pharmaceuticals, Inc",
"Amended & Restated Bylaws of Avanir Pharmaceuticals, Inc",
"Avanir Pharmaceuticals, Inc. 2014 Incentive Plan - Form of Incentive Stock Option Agreement (Employees)",
"Avanir Pharmaceuticals, Inc. 2014 Incentive Plan - Form of Non-Statutory Stock Option Agreement (Employees)",
"Avanir Pharmaceuticals, Inc. 2014 Incentive Plan - Form of Restricted Stock Unit Agreement (Employees)",
"Avanir Pharmaceuticals, Inc. 2014 Incentive Plan - Form of Restricted Stock Unit Agreement (Directors)"
02/05/2014 8-K Quarterly results
Docs: "AVANIR PHARMACEUTICALS REPORTS FISCAL 2014 FIRST QUARTER FINANCIAL AND BUSINESS RESULTS"
01/17/2014 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Avanir Pharmaceuticals Pre-announces Preliminary Fiscal 2014 First Quarter Financial Information"
01/10/2014 8-K Resignation/termination of a director
12/10/2013 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
Docs: "Second Amendment to Sales Agreement",
"Opinion of Ropes & Gray LLP",
"Avanir Pharmaceuticals Reports Fiscal 2013 Fourth Quarter Financial and Year-End Business Results"
11/15/2013 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Material Modifications to Rights ...
Docs: "Certificate of Elimination of Series A Junior Participating Cumulative Preferred Stock",
"Amendment and Termination of Stockholder Rights Agreement, by and between Avanir Pharmaceuticals, Inc. and American Stock Transfer & Trust Company, LLC"
10/29/2013 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Corporate Update Presentation"
10/29/2013 8-K Form 8-K - Current report
08/12/2013 8-K Entry into a Material Definitive Agreement
08/06/2013 8-K Quarterly results
Docs: "Avanir Pharmaceuticals Reports Fiscal 2013 Third Quarter Financial and Business Results"
03/12/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/20/2013 8-K Submission of Matters to a Vote of Security Holders
12/06/2012 8-K Resignation/termination of a director
12/04/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "Memorandum Opinion, filed December 3, 2012, issued by The United States District Court for the District of Delaware"
11/30/2012 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "AVANIR PHARMACEUTICALS PRE-ANNOUNCES PRELIMINARY FISCAL 2012 FOURTH QUARTER RESULTS AND PROVIDES CLINICAL STUDY UPDATE"
11/21/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/08/2012 8-K Quarterly results
Docs: "AVANIR PHARMACEUTICALS REPORTS FISCAL 2012 THIRD QUARTER FINANCIAL AND BUSINESS RESULTS 37% Increase in NUEDEXTA Net Sales to Wholesalers over the Previous Quarter"
06/05/2012 8-K Form 8-K - Current report
05/08/2012 8-K Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment...
Docs: "AVANIR PHARMACEUTICALS REPORTS FISCAL 2012 SECOND QUARTER FINANCIAL AND BUSINESS RESULTS -Company Announces $30 million Term Loan Agreement- -NUEDEXTA Gross Sales to Wholesalers Increased 42% over the Previous Quarter-"
02/29/2012 8-K Form 8-K - Current report
02/17/2012 8-K Submission of Matters to a Vote of Security Holders, Other Events
12/12/2011 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy